Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
Ovid Therapeutics Inc OVID
$2.40
▼ -3.81%
($-0.10)
Open
$2.49
Prev Close
$2.50
Day Range
$2.40 – $2.51
52W Range
$1.18 – $3.11
Market Cap
$468.71M
Beta
0.28
EPS (TTM)
$-0.25
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-05-05 |
| Shares Out. | 186,640,000 |
| Website | ovidrx.com/ ↗ |
| Phone | 12127764381 |
| Employees | 23 |
| Revenue | $733,000 |
| Gross Profit | $733,000 |
| Net Income | -$15.0M |
| Free Cash Flow | -$54.8M |
| Total Assets | $232.0M |
| Total Liabilities | $22.1M |
| Equity | $209.9M |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ovid Therapeutics Inc is a publicly traded company under the ticker symbol OVID on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)